Related references
Note: Only part of the references are listed.Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
N. Bouwer et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G. Curigliano et al.
ANNALS OF ONCOLOGY (2020)
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy
Yao Wong et al.
ONCOLOGIST (2019)
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
F. Lynce et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
T. G. Steenbruggen et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction
Somaira Nowsheen et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
J. Baselga et al.
ANNALS OF ONCOLOGY (2014)
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Juan Carlos Plana et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2014)
Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer
G. Gullo et al.
ANNALS OF ONCOLOGY (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
UK audit of left ventricular ejection fraction estimation from equilibrium ECG gated blood pool images
JV Skrypniuk et al.
NUCLEAR MEDICINE COMMUNICATIONS (2005)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
